PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA) orp ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Visual auras, like those that occur in migraines, may be signs of small injuries to the brain’s visual cortex, according to a clinical trial at UC San Francisco that tracked the appearance of these ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

Is Pola-R-CHP a suitable standard for all or should the lack of survival benefit and differential subgroup responses give pause in treating all patients who qualify?

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...